Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples